Global Point-of-Care Diagnostics Market 2022: Developments Including AI Integration Drive Sector Forward –

Global Point-of-Care Diagnostics Market 2022: Developments Including AI Integration Drive Sector Forward –

DUBLIN–()–The “Global Point-of-Care Diagnostics Market, By Product Type, By End Users, By Platform: Forecast And Analysis 2022-2028” Report has been added to offering.

The global point-of-care diagnostics market was valued at USD 46.65 billion in 2021 and is expected to reach USD 51.94 billion by 2028, at a CAGR of 5.2% over the forecast period (2022 -2028).

For the investigation (diagnosis and monitoring) of a variety of diseases, such as cancer, diabetes, heart disease and others, point-of-care (POC) diagnostics are used. They are medical tools that are used to obtain an immediate response. The increase in the prevalence of chronic and infectious diseases in developing economies is one of the growth factors of the market for diagnostics at the point of care. Globally, the prevalence of chronic diseases such as diabetes, rheumatism, and cancer is increasing for a number of reasons, including an aging population, sedentary lifestyles, poor eating habits, and environmental factors.

For example, chronic diseases claim the lives of more than 38 million people worldwide each year. Every year 17.5 million people die from chronic diseases related to the cardiovascular system, followed by cancer (8.2 million), respiratory diseases (4 million) and diabetes (1.5 million). 82% of deaths from chronic disorders are caused by the aforementioned diseases. Point-of-care diagnostics are becoming increasingly popular with patients around the world, as samples are taken from the patient’s location for testing and results can be obtained in a remarkably short period of time due to the use of microfluidics, chips and nanodiagnostics.

Segments covered in this report

The global Point of Care Diagnostics market is segmented on the basis of product type, end-users, and platform.

  • Based on product type, the market is further segmented into Glucose Tests, Hb1Ac Tests, Coagulation Tests, Fertility/Pregnancy, Infectious Diseases (HIV POC, Clostridium Difficile POC, HBV POC, Pneumonia or Streptococcus Associated Infections, Virus respiratory syncytial (RSV) POC , HPV POC, Influenza/Flu POC, HCV POC, MRSA POC, TB and Drug-Resistent TB POC, HSV POC, COVID-19, Other infectious diseases), cardiac markers, thyroid stimulating hormone, hematology, primary care systems, decentralized clinic Chemistry, stool, lipid analysis, cancer marker, blood gases/electrolytes, ambulatory chemistry, drug of abuse (DOA) analysis, urinalysis/nephrology.

  • Based on end users, the global point-of-care diagnostics market is further segmented into clinics, hospitals, home care, assisted living healthcare facilities, and laboratory.

  • Based on the platform, the market is segmented as Lateral Flow Assay, Test Strips, Microfluidics, Molecular Diagnostics, Immunoassays.


Globally, there has been a significant increase in the occurrence of chronic diseases such as cardiovascular problems, diabetes, and numerous infectious diseases. One of the main factors driving the demand for point-of-care diagnostics during the forecast period is the increasing occurrence of such disorders.

According to the United Nations, around 38 million people have HIV/AIDS in 2019. There were 1.8 million young people and 36.2 million adults among them. Additionally, human respiratory syncytial virus (RSV) is one of the most common viruses responsible for respiratory tract infections. According to the CDC, between 4 and 5 million children worldwide suffer from respiratory syncytial virus (RSV) lower respiratory tract infections each year. Similarly, according to the IDF Diabetes Atlas, 206.0 million adults worldwide had diabetes in 2021.


Due to a large number of pre- and post-analytical errors, point-of-care testing findings do not align well with central laboratory procedures. Inadequate indications for performing the test, inadequate sampling times and techniques, insufficient information about the patient’s condition and other variables such as fasting before functional tests or differences in posture/position during similar tests are examples of preanalytical errors. for point of care testing. Post-analytical errors, on the other hand, include insufficient technical validation, incorrect result assignment, and data storage issues.


Major market participants have increased their focus on the use of new technologies, such as artificial intelligence, in the production of efficient diagnostics at the point of care. Significant advances in point-of-care testing devices have been the result of lab-on-a-chip platforms, wearable technologies, and smartphone-based technological innovations. Cloud-based intelligent systems have paved the way for future revolutions.

Companies mentioned

  • Abbott Laboratories (USA)

  • Siemens Healthineers AG (Germany)

  • Quidel Corporation (USA)

  • F. Hoffman-La Roche Ltd. (Switzerland)

  • Danaher Corporation (USA)

  • Becton, Dickinson and Company (USA)

  • Chembio Diagnostics (USA)

  • EKF Diagnostics (UK)

  • Trinity Biotech plc (Ireland)

  • Instrumentation Laboratory (USA)

  • Nova biomedical (USA)

  • PTS Diagnostics (US)

  • Sekisui Diagnostics (USA)

  • Thermo Fisher Scientific (USA)

  • BioMerieux SA (France)

For more information on this report, visit

Leave a Comment